Office of Professional Education

Two free CME/CNE/CPE live webinars

Virus-neutralizing monoclonal antibodies (NAbs) have the potential to change the care of COVID-19 from a reactive approach for people with severe disease to a proactive approach that prevents those with milder or more moderate disease from progressing. This change in the COVID-19 treatment paradigm places clinicians in outpatient settings on the front lines of care for those at high risk of COVID-19 progression to severe disease. 

Join us for a 2-session educational experience designed to help healthcare providers recognize patients with mild to moderate COVID-19 at high risk of progression, counsel and educate patients and other care providers on those risks and the available treatment options, and orient patients to infusion centers.
 

Session Dates and Times:

 

Session 1: Evidence and the Evolving Treatment Landscape for COVID-19 with Virus Neutralizing Antibodies

  • Thursday, May 13, 2021 – 10:00 am to 11:00 am MT 
    (Begins at 12:00 pm ET, 11:00 am CT, and 9:00 am PT)

    ► Register here for the May 13th webinar.

 

Session 2: Enhancing Access to COVID-19 Breakthrough Therapy with Virus Neutralizing Antibodies: Strategies for Equitable Care

  • Friday, May 21, 2021 – 3:00 pm to 4:00 pm MT 
    (Begins at 5:00 pm ET, 4:00 pm CT, and 2:00 pm PT)

    ►Register here for the May 21st webinar.

 


Target Audience:

The primary intended audience for this education includes practicing US HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, registered nurses, and pharmacists.

 

Learning Objectives:

Upon completion of these activities, the participant will be better able to:

  1. Understand the rationale for and process by which the FDA issues an EUA for agents developed for the treatment of COVID-19
  2. Recognize SARS-CoV-2-infected patients with mild to moderate COVID-19 who could benefit from NAbs treatments 
  3. NAbsCounsel and orient SARS-CoV-2-infected patients displaying mild to moderate symptoms to appropriate treatment or care based on their risk for hospitalization

 

Program Faculty:

Rebecca C. Keith, MD
Associate Professor
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
Interstitial Lung Disease Program
Autoimmune Lung Center
National Jewish Health, Denver, CO
 
Jared J. Eddy, MD, MPhil, MSc
Assistant Professor
Director of Infection Prevention & Antimicrobial Stewardship
Division of Mycobacterial & Respiratory Infections
Department of Medicine
National Jewish Health, Denver, CO

 

Contact:

For questions, please email the Office of Professional Education at National Jewish Health proed@njhealth.org or call 303.398.1000 or 800.844.2305. 


Accreditation and Designation Statements:

Physicians:  National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health designates each live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses: Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours for each activity.

Pharmacists: National Jewish Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

National Jewish Health designates each live activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. 

Session 1: Universal Activity Number: 0831-0000-21-014-L01-P. Activity Type: Knowledge-based.
Session 2: Universal Activity Number: 0831-0000-21-015-L01-P. Activity Type: Knowledge-based.

To earn credit, attendees must participate in the live activity, pass the post-test with a minimum score of 70%, and complete the activity evaluation. 

Support:

This educational activity is supported by an educational grant from Eli Lilly.